First FDA-approved drug for vitiligo is a ‘game changer’ (

August 9, 2022
First FDA-approved drug for vitiligo is a ‘game changer’

Vitiligo is an autoimmune condition affecting nearly 2 million Americans. It causes patches of skin to lose color or turn white, and it has no cure. But a new treatment approved by the Food and Drug Administration offers hope.

“The introduction of topical Ruxolitinib is a game changer in the management of vitiligo,” said Dr. Adam Friedman, chair of dermatology at The George Washington University School of Medicine and Health Sciences. “Vitiligo imposes a large burden on patients’ lives and many patients suffer from shame and embarrassment, low self-confidence and social isolation,” he said.

The topical cream takes about six months to work and might not be covered by insurance. 

“It will be an insurance by insurance situation,” Friedman said. “Given this is the only FDA-approved therapy, our hope is that insurance companies will cover it to provide relief for the up to 2% of the population that suffers with this condition.”


Read the full article on

Latest News

November 30, 2022
Nearly 250,000 people in the United States will receive a lung cancer diagnosis in 2022, according to the American Cancer Society. However, thanks in part to a drop in smoking nationwide, the number of new lung cancer diagnoses is declining steadily each year.
November 9, 2022
The GW Medical Faculty Associates is pleased to announce the appointment of Barry Browning to serve as the executive director for surgical services. In this role, Browning is responsible for recruiting and managing highly qualified managers across multiple locations and functions within the areas…
November 7, 2022
The George Washington University (GW) School of Medicine and Health Sciences (SMHS) is pleased to welcome LaQuandra S. Nesbitt, MD, MPH, immediate-past director of DC Health, to serve as the new executive director of the Center for Population Health Sciences and Health Equity. In this role, Nesbitt…